Onkologie. 2024:18(5):296-298 | DOI: 10.36290/xon.2024.061

Serous tubal intraepithelial carcinoma and management after its incidental finding

Magdalena Plch, Gabriel Jelenek, Richard Feranec, Josef Chovanec
Oddělení gynekologické onkologie Kliniky operační onkologie Masarykova onkologického ústavu, Brno
Oddělení gynekologické onkologie Kliniky operační onkologie, Lékařská fakulta Masarykovy univerzity, Brno

Serous tubal intraepithelial carcinoma (STIC) is considered as a precursor of high-grade serous carcinoma of the pelvis (HGSC), which includes ovarian, tubal and peritoneal carcinomas. STIC is an early morphologically recognizable lesion in the pathogenesis of HGSC and is found predominantly in the distal part of the fallopian tube. Despite a great progress in elucidating the pathogenesis of ovarian carcinomas and the introduction of new pathological procedures for the diagnosis of precursor lesions of HGSC, there remain many unanswered questions.

Keywords: high grade serous carcinoma, serous tubular intraepithelial carcinoma, BRCA, precursor lesions of fallopian tube, SEE-FIM protocol.

Accepted: November 18, 2024; Published: November 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Plch M, Jelenek G, Feranec R, Chovanec J. Serous tubal intraepithelial carcinoma and management after its incidental finding. Onkologie. 2024;18(5):296-298. doi: 10.36290/xon.2024.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 28.11.2025

    References

    1. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230-236. doi: 10.1097/01.pas.0000180854.28831.77. PMID: 16434898. Go to original source... Go to PubMed...
    2. van den Berg CB, Dasgupta S, Ewing-Graham PC, et al. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. Gynecologic Oncology. Volume 187. Pages 113-119 (August 2024). doi: 10.1016/j.ygyno.2024.05.010. Go to original source... Go to PubMed...
    3. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi: 10.1001/jama.2017.7112. PMID: 28632866. Go to original source... Go to PubMed...
    4. van der Ven J, Linz VC, Anic K, et al. A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany. Arch Gynecol Obstet. 2023;308(2):527-534. doi: 10.1007/s00404-023-06919-8. Epub 2023 Jan 27. PMID: 36707423; PMCID: PMC10293341. Go to original source... Go to PubMed...
    5. Steenbeek MP, van Bommel MHD, Bulten J, et al. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022;40(17):1879-1891. doi: 10.1200/JCO.21.02016. Epub 2022 Mar 18. PMID: 35302882; PMCID: PMC9851686. Go to original source... Go to PubMed...
    6. Linz VC, Löwe A, van der Ven J, et al. Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature. Front Oncol. 2022;12:951292. doi: 10.3389/fonc.2022.951292. PMID: 36119503; PMCID: PMC9472545. Go to original source... Go to PubMed...
    7. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17. PMID: 31099893. Go to original source... Go to PubMed...
    8. Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. PMID: 27012190; PMCID: PMC5808151. Go to original source... Go to PubMed...
    9. Morrison JC, Blanco LZ Jr, Vang R, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol. 2015;39(4):442-453. doi: 10.1097/PAS.0000000000000352. PMID: 25517955. Go to original source... Go to PubMed...
    10. Lee S, Nelson G, Duan Q, et al. Precursor lesions and prognostic factors in primary peritoneal serous carcinoma. Int J Gynecol Pathol. 2013;32(6):547-555. doi: 10.1097/PGP.0b013e31827f3fa8. PMID: 24071870. Go to original source... Go to PubMed...
    11. Bogaerts JMA, Steenbeek MP, van Bommel MHD, et al. Recommendations for diagnosing STIC: a systematic review and meta-analysis. Virchows Arch. 2022;480(4):725-737. doi: 10.1007/s00428-021-03244-w. Epub 2021 Dec 1. PMID: 34850262; PMCID: PMC9023413. Go to original source... Go to PubMed...
    12. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3-9. doi: 10.1097/GCO.0b013e328011a21f. PMID: 17218844. Go to original source... Go to PubMed...
    13. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093. doi: 10.1038/s41467-017-00962-1. PMID: 29061967; PMCID: PMC5653668. Go to original source... Go to PubMed...
    14. Sowamber R, Lukey A, Huntsman D, et al. Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. Curr Oncol. 2023;30(12):10179-10194. doi: 10.3390/curroncol30120741. PMID: 38132375; PMCID: PMC10742141. Go to original source... Go to PubMed...
    15. Weinberger V, Bednarikova M, Cibula D, et al. Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management. Expert Rev Anticancer Ther. 2016;16(12):1311-1321. doi: 10.1080/14737140.2016.1247699. Epub 2016 Oct 22. PMID: 27732120. Go to original source... Go to PubMed...
    16. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-169. doi: 10.1097/01.pas.0000213335.40358.47. PMID: 17255760. Go to original source... Go to PubMed...
    17. Ledermann JA, Matias-Guiu X, Amant F, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35(3):248-266. doi: 10.1016/j.annonc.2023.11.015. Epub 2024 Feb 1. PMID: 38307807. Go to original source... Go to PubMed...
    18. Maritschnegg E, Heitz F, Pecha N, et al. Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. Int J Gynecol Cancer. 2018;28(9):1692-1698. doi: 10.1097/IGC.0000000000001361. PMID: 30376484; PMCID: PMC6254778. Go to original source... Go to PubMed...
    19. Chay WY, McCluggage WG, Lee CH, et al. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer. 2016;26(3):431-436. doi: 10.1097/IGC.0000000000000639. PMID: 26807643. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.